miR‑371‑5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2

Deng,Bifan; Su,Feiqun; Xie,Ruibin; Tang,Weiguang

doi:10.3892/ol.2018.8481

miR‑371‑5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2

Authors:
- Bifan Deng
- Feiqun Su
- Ruibin Xie
- Weiguang Tang
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, Hezhou Renmin Hospital, Hezhou, Guangxi 542899, P.R. China, Department of Nursing, Hezhou Renmin Hospital, Hezhou, Guangxi 542899, P.R. China, Department of Cardiovascular Medicine, Hezhou Renmin Hospital, Hezhou, Guangxi 542899, P.R. China, Department of Nephrology and Rheumatology, Hezhou Renmin Hospital, Hezhou, Guangxi 542899, P.R. China
Published online on: April 12, 2018 https://doi.org/10.3892/ol.2018.8481
Pages: 9209-9215
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression and function of microRNA (miR)‑371‑5p in nasopharyngeal carcinoma (NPC). The levels of miR‑371‑5p were analyzed in nasopharyngeal epithelium tissues, NPC tissues, human NPC cell lines and NP69 cells using reverse transcription‑quantitative polymerase chain reaction analysis. The association between the level of miR‑371‑5p and clinicopathological variables was also investigated. Cell proliferation was determined using an MTT assay, and the activities of cell metastasis were determined using wound healing and Transwell migration assays. To assess whether miR‑371‑5p can combine with the targeting sequence of B‑cell lymphoma 2 (BCL2) mRNA or not, a luciferase activity assay was performed. An animal experiment was used to examine the effect of miR‑371‑5p on the development of NPC. The results revealed that the expression of miR‑371‑5p was reduced in NPC samples and NPC cells. The level of miR‑371‑5p was associated with clinical stage and distant metastasis in patients with NPC, and was inversely associated with the protein level of BCL‑2 in NPC tissues. The upregulation of miR‑371‑5p reduced cell growth, migration and invasion, and inhibited carcinoma growth through targeting BCL2 mRNA. Taken together, the regulation of miR‑371‑5p was shown to offer potential as a novel treatment approach for NPC.

View Figures

View References

1	Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX and Chen WQ: Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 33:381–387. 2014.PubMed/NCBI
2	Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC and Wang AY: Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 33:501–508. 2003. View Article : Google Scholar : PubMed/NCBI
3	Liang Z and Xi Y: MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer. Chin J Nat Med. 14:881–887. 2016.PubMed/NCBI
4	Xing Z, Li D, Yang L, Xi Y and Su X: MicroRNAs and anticancer drugs. Acta Biochim Biophys Sin (Shanghai). 46:233–239. 2014. View Article : Google Scholar : PubMed/NCBI
5	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
6	Qin X, Chen J, Wu L and Liu Z: miR-30b-5p acts as a tumor suppressor, repressing cell proliferation and cell cycle in human hepatocellular carcinoma. Biomed Pharmacother. 89:742–750. 2017. View Article : Google Scholar : PubMed/NCBI
7	Wang L, Wu L and Wu J: Downregulation of miR-154 in human glioma and its clinicopathological and prognostic significance. J Int Med Res. 44:994–1001. 2016. View Article : Google Scholar : PubMed/NCBI
8	Tian F, Chen J, Zheng S, Li D, Zhao X, Jiang P, Li J and Wang S: miR-124 targets GATA6 to suppress cholangiocarcinoma cell invasion and metastasis. BMC Cancer. 17:1752017. View Article : Google Scholar : PubMed/NCBI
9	He B, Xu Z, Chen J, Zheng D, Li A and Zhang LS: Upregulated microRNA-143 inhibits cell proliferation in human nasopharyngeal carcinoma. Oncol Lett. 12:5023–5028. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gao W, Lam JW, Li JZ, Chen SQ, Tsang RK, Chan JY and Wong TS: MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. Oncol Rep. 37:913–920. 2017. View Article : Google Scholar : PubMed/NCBI
11	Huang T, Yin L, Wu J, Gu JJ, Wu JZ, Chen D, Yu HL, Ding K, Zhang N, Du MY, et al: MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-kB axis. J Exp Clin Cancer Res. 35:1882016. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Lv Z, He G, Wang J, Zhang X, Lu G, Ren X, Wang F, Zhu X, Ding Y, et al: The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Oncotarget. 6:9099–9112. 2015.PubMed/NCBI
13	He D, Miao H, Xu Y, Xiong L, Wang Y, Xiang H, Zhang H and Zhang Z: miR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival. PloS One. 9:e1129302014. View Article : Google Scholar : PubMed/NCBI
14	Liu RY, Diao CF, Zhang Y, Wu N, Wan HY, Nong XY, Liu M and Tang H: miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells. Cancer Lett. 335:351–60. 2013. View Article : Google Scholar : PubMed/NCBI
15	Igney FH and Krammer PH: Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Boil. 71:907–920. 2002.
16	Lessene G, Czabotar PE and Colman PM: BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 7:989–1000. 2008. View Article : Google Scholar : PubMed/NCBI
17	Bajwa N, Liao C and Nikolovska-Coleska Z: Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review. Expert Opin Ther Pat. 22:37–55. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A and Scorilas A: Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: An unfavorable and independent prognostic factor. Tumour Boil. 31:391–399. 2010. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Gomes BC, Rueff J and Rodrigues AS: MicroRNAs and cancer drug resistance. Methods Mol Biol. 1395:137–162. 2016. View Article : Google Scholar : PubMed/NCBI
21	Cory S, Huang DC and Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
22	Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:334–336. 1990. View Article : Google Scholar : PubMed/NCBI
23	Choi J, Choi K, Benveniste EN, Rho SB, Hong YS, Lee JH, Kim J and Park K: Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res. 65:5554–5560. 2005. View Article : Google Scholar : PubMed/NCBI
24	Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:362–366. 1998.PubMed/NCBI
25	He CY and Yang J: miR-187 induces apoptosis of SiHa cervical carcinoma cells by downregulating Bcl-2. Genet Mol Res. 16:gmr160189692017. View Article : Google Scholar
26	Ma Z, Luo Y and Qiu M: miR-143 Induces the apoptosis of prostate cancer LNCap cells by suppressing Bcl-2 expression. Med Sci Monit. 23:359–65. 2017. View Article : Google Scholar : PubMed/NCBI